Stephen K. L. Chia
MD, FRCPC
Professor of MedicineMedical Oncology
British Columbia Cancer Agency
University of British Columbia
Co-chair CCTG Breast Disease Site
Vancouver (BC)
Joyce A O’Shaughnessy
MD
Celebrating Women EndowedChair in Breast Cancer Research
Co-Chair, Breast Cancer Research Program
Chair, Breast Cancer Prevention Research
Baylor University Medical Center
Texas Oncology/US Oncology Network
Dallas (TX)
Christine Brezden-Masley
MD, PhD, FRCPC
Medical Oncologist, St. Michael’s HospitalAssociate Professor, University of Toronto
Co-Director, Hem. Oncology Clinical Research Group
Associate Scientist, Li Ka Shing Knowledge Institute
President, Canadian Cardio-Oncology Network
Founder, COMET Clinical Trials Consortium Consortium
Toronto (ON)
Scott Edwards
PharmD, MSc (Oncol)
Clinical Oncology Pharmacy SpecialistCancer Care Program,
Eastern Health Assistant Professor,
Memorial University
St. John’s (NL)
This website is independent of the CBCS conference and developed to facilitate registration to the Satellite Symposia sponsored by Eli Lilly Canada Inc
DATE
Thursday, June 13, 2019You must be registered for the CBCS conference to attend this satellite symposium
TIME
5 – 6 PM (Refreshments will be served)LOCATION
Queen's Quay Room — The Westin Harbour Castle, TorontoABOUT THE SYMPOSIUM
This symposium will engage clinicians to optimize the management of patients with HR+/HER2- mBC being treated with CDK4/6 inhibitors in order to achieve best clinical outcomes. Presenters include both Canadian and US experts who share their clinical experiences through interview questions and interactive case-based presentations and discussions.
LEARNING OBJECTIVES
At the end of this learning activity, participants will be able to:- Review the latest evidence and ongoing research in the area of HR+/HER2- metastatic breast cancer to achieve best outcomes for these patients
- Recognize best practices in the treatment of metastatic breast cancer with CDK4/6 inhibitors through discussions with experts in US and Canada
- Explore heterogeneity in HR+/HER2- metastatic breast cancer and its implications for treatment choices through case discussions